10-QPeriod: Q3 FY2009

VERTEX PHARMACEUTICALS INC / MA Quarterly Report for Q3 Ended Sep 30, 2009

Filed November 9, 2009For Securities:VRTX

Summary

Vertex Pharmaceuticals Inc. reported a net loss of $149.6 million for the third quarter of 2009, an increase from the $130.0 million net loss in the same period of 2008. The company's revenues also saw a decline, falling to $25.0 million from $31.6 million year-over-year, primarily due to the absence of significant milestone payments received in the prior year. Despite the increased net loss and lower revenues, Vertex made strategic financial moves, including issuing secured notes and selling rights to future milestone payments, which generated significant cash inflows. The company's balance sheet showed a substantial increase in total assets, driven by the acquisition of ViroChem Pharma Inc. and strong cash reserves. Vertex continues to heavily invest in research and development, particularly in its lead drug candidate, telaprevir for Hepatitis C, and its cystic fibrosis programs, indicating a long-term focus on pipeline development despite near-term financial pressures.

Financial Highlights

25 data points
Beta

Revenue

$24.96M

Net Income

-$149.56M

-599.3% Net Margin

EPS (Diluted)

$-0.84

Cash & Equivalents

$559.13M

Free Cash Flow

-$26.39M

Financial Statements
Beta
Revenue$24.96M
R&D Expenses$132.13M
SG&A Expenses$36.57M
Operating Expenses$173.19M
Operating Income-$148.23M
Interest Expense$1.93M
Net Income-$149.56M
EPS (Basic)$-0.84
EPS (Diluted)$-0.84
Shares Outstanding (Basic)178.74M
Shares Outstanding (Diluted)178.74M

Key Highlights

  • 1Reported a net loss of $149.6 million for Q3 2009, an increase from $130.0 million in Q3 2008.
  • 2Total revenues decreased by 21% to $25.0 million in Q3 2009 compared to $31.6 million in Q3 2008, largely due to a lack of milestone payments.
  • 3Acquired ViroChem Pharma Inc. in March 2009 for $100 million cash and stock, significantly increasing intangible assets (in-process R&D).
  • 4Issued $155.0 million in secured notes due 2012 and sold rights to $95.0 million in future milestone payments in September 2009, generating cash but creating new liabilities.
  • 5Ended the quarter with $856.6 million in cash, cash equivalents, and marketable securities, an increase from $832.1 million at the end of 2008, providing a substantial liquidity buffer.
  • 6Continued significant investment in R&D, with expenses totaling $132.1 million in Q3 2009, up slightly from $131.7 million in Q3 2008, indicating a commitment to pipeline development, particularly for telaprevir (HCV) and cystic fibrosis candidates.

Frequently Asked Questions

Vertex Pharmaceuticals is currently operating at a net loss, which increased in the third quarter of 2009 compared to the same period in 2008. Revenue also declined, primarily due to the absence of significant milestone payments received in the prior year. However, the company possesses a strong cash position of over $850 million and has actively managed its debt and secured new financing through note issuance and milestone payment rights sales. The company is making substantial investments in research and development, particularly for its lead drug candidate telaprevir, indicating a focus on future growth despite current profitability challenges.

Vertex is heavily focused on the development of telaprevir for Hepatitis C, with Phase 3 trials nearing completion and an anticipated NDA submission in the second half of 2010. Significant progress is also being made in its cystic fibrosis program with VX-770 and VX-809, with registration programs initiated or underway. The acquisition of ViroChem brought in two clinical-stage HCV polymerase inhibitors (VX-222 and VX-759), bolstering the HCV pipeline. The company is also developing VX-509 for immune-mediated inflammatory diseases.

The acquisition of ViroChem in March 2009 for $100 million in cash and significant stock issuance has substantially increased Vertex's total assets. It added $525.9 million in intangible assets, primarily in-process research and development for HCV drug candidates, and $26.1 million in goodwill. This acquisition also resulted in $7.8 million in acquisition-related expenses and a deferred tax liability of $162.5 million recorded on the balance sheet.

In September 2009, Vertex completed two significant financial transactions related to its telaprevir collaboration. First, it issued $155.0 million in secured notes due 2012 for $122.2 million, secured by future telaprevir milestone payments. Second, it sold rights to $95.0 million of future telaprevir milestone payments for $32.8 million. These transactions provided immediate cash but created liabilities and restructured how future milestone payments will be recognized and utilized, impacting future liquidity and financial reporting.